You still haven’t acknowledged my replies re: i) the irrelevance of the relapse rate as an independent efficacy metric; or ii) de facto BID dosing whenever ribavirin is included.
p.s. You ought to lighten up, IMO. It’s not a violation of board protocol to ask posters about their position in a given stock.
Market Data 
Markets 
AI
